Featured Research

from universities, journals, and other organizations

New Vaccine Being Tested In Prostate Cancer Patients

Date:
November 23, 1998
Source:
American Chemical Society
Summary:
Chemists at the Sloan-Kettering Institute for Cancer Research have created a novel vaccine they hope will thwart prostate cancer. Now in early human trials, the vaccine is the first made synthetically to target abundant, but elusive, carbohydrates on the surface of tumor cells.

Chemists at the Sloan-Kettering Institute for Cancer Research have created a novel vaccine they hope will thwart prostate cancer. Now in early human trials, the vaccine is the first made synthetically to target abundant, but elusive, carbohydrates on the surface of tumor cells.

The development will be outlined in the November 20 Web edition of the Journal of the American Chemical Society, published by the American Chemical Society, the world's largest scientific society. It is scheduled to appear in the print version of the peer-reviewed journal on November 25.

Using vaccines to stimulate an immune response against cancer typically focuses on proteins, which are relatively easy to make but often arelodged within cells and not easily accessible to antibodies. Most of the good targets, or antigens, on a cancer cell's surface are not proteins, however. Instead they are small, difficult to synthesize carbohydrates whose immunogenicity is not well-understood.

"Normally the carbohydrates are much more complex in normal cells. In cancer cells they're often very different," says lead author and Sloan Kettering Institute for Cancer Research chemist Scott D. Kuduk, Ph.D. The difference should enable scientists to exclusively target cancer.

Kuduk, who works in the lab of Kettering Chair and Director of Bioorganic Chemistry, Samuel J. Danishefsky, Ph.D., says their group successfully synthesized two key tumor carbohydrate antigens -- called TF and Tn. They then clustered the antigens as they occur naturally and attached them to proteins which help produce an immune response. "Through chemistry, we were able to make substantial quantities of the material that allowed us to then do the testing," adds Kuduk. In mice, the Tn-protein complex was especially effective at triggering antibody production.

"It's a wonderful antigen for prostate cancer because Tn is one of the main antigens on prostate cancer cells," according to co-author and Sloan Kettering Immunologist Philip O. Livingston, M.D., who calls the advance "more promising than other approaches."

The new vaccine is being given to patients who have undergone prostate cancer surgery, hoping to ward off a recurrence. Though it is too early to know whether a series of vaccinations will provide an adequate defense, Livingston says patients are definitely producing antibodies against Tn. Scientists hope the vaccines will specifically attack prostate cancer cells, thereby permanently curbing cancer and reducing the side effects usually associated with chemotherapy.

###

A nonprofit organization with a membership of more than 155,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "New Vaccine Being Tested In Prostate Cancer Patients." ScienceDaily. ScienceDaily, 23 November 1998. <www.sciencedaily.com/releases/1998/11/981120075658.htm>.
American Chemical Society. (1998, November 23). New Vaccine Being Tested In Prostate Cancer Patients. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/1998/11/981120075658.htm
American Chemical Society. "New Vaccine Being Tested In Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/1998/11/981120075658.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Cases Keep Coming for Monrovia's Island Hospital

Ebola Cases Keep Coming for Monrovia's Island Hospital

AFP (Oct. 1, 2014) A look inside Monrovia's Island Hospital, a key treatment centre in the fight against Ebola in Liberia's capital city. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Ebola Puts Stress on Liberian Health Workers

Ebola Puts Stress on Liberian Health Workers

AP (Oct. 1, 2014) The Ebola outbreak is putting stress on first responders in Liberia. Ambulance drivers say they are struggling with chronic shortages of safety equipment and patients who don't want to go to the hospital. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Doctors Reassure Public Ebola Patient Won't Cause Outbreak

Newsy (Sep. 30, 2014) After the announcement that the first U.S. patient had been diagnosed with Ebola, doctors were quick to say a U.S. outbreak is highly unlikely. Video provided by Newsy
Powered by NewsLook.com
TX Hospital Confirms Patient Admitted With Ebola

TX Hospital Confirms Patient Admitted With Ebola

AP (Sep. 30, 2014) Medical officials from Texas Health Presbyterian Hospital confirm they are treating a patient with the Ebola virus, the first case found in the US. (Sept. 30 Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins